The expression of 70 apoptosis genes in relation to lineage, genetic subtype, cellular drug resistance, and outcome in childhood acute lymphoblastic leukemia.
暂无分享,去创建一个
Cheng Cheng | W. Evans | M. D. Den Boer | R. Pieters | M. Cheok | G. Janka-Schaub | U. Göbel | U. Graubner | K. Kazemier | A. Holleman | R. D. De Menezes | M. D. den Boer | R X de Menezes
[1] Hiroshi Yasui,et al. Seliciclib (CYC202 or R-roscovitine), a small-molecule cyclin-dependent kinase inhibitor, mediates activity via down-regulation of Mcl-1 in multiple myeloma. , 2005, Blood.
[2] R. Kim,et al. Recent advances in understanding the cell death pathways activated by anticancer therapy , 2005, Cancer.
[3] Masakazu Toi,et al. Nuclear factor-κB inhibitors as sensitizers to anticancer drugs , 2005, Nature Reviews Cancer.
[4] D. Coppola,et al. Mcl-1 regulates survival and sensitivity to diverse apoptotic stimuli in human non-small cell lung cancer cells , 2005, Cancer biology & therapy.
[5] Cheng Cheng,et al. Improved outcome for children with acute lymphoblastic leukemia: results of Total Therapy Study XIIIB at St Jude Children's Research Hospital. , 2004, Blood.
[6] T. Stankovic,et al. Apoptotic resistance to ionizing radiation in pediatric B-precursor acute lymphoblastic leukemia frequently involves increased NF-kappaB survival pathway signaling. , 2004, Blood.
[7] Cheng Cheng,et al. Gene-expression patterns in drug-resistant acute lymphoblastic leukemia cells and response to treatment. , 2004, The New England journal of medicine.
[8] Peter Scheurich,et al. NFκB activation by Fas is mediated through FADD, caspase-8, and RIP and is inhibited by FLIP , 2004, The Journal of cell biology.
[9] S. Knudsen,et al. Prediction of immunophenotype, treatment response, and relapse in childhood acute lymphoblastic leukemia using DNA microarrays , 2004, Leukemia.
[10] M. D. Boer,et al. In vitro drug-resistance profile in infant acute lymphoblastic leukemia in relation to age, MLL rearrangements and immunophenotype , 2004, Leukemia.
[11] W. Kern,et al. Satelite Symposium V, Meet-the-Professor Sessions I and II, Main Sessions I-IX , 2004, Annals of Hematology.
[12] M. D. Den Boer,et al. Resistance to different classes of drugs is associated with impaired apoptosis in childhood acute lymphoblastic leukemia. , 2003, Blood.
[13] P. Hains,et al. Proteome Analysis of Vinca Alkaloid Response and Resistance in Acute Lymphoblastic Leukemia Reveals Novel Cytoskeletal Alterations* , 2003, Journal of Biological Chemistry.
[14] J. Downing,et al. Classification of pediatric acute lymphoblastic leukemia by gene expression profiling. , 2003, Blood.
[15] M. D. Boer,et al. Patient stratification based on prednisolone-vincristine-asparaginase resistance profiles in children with acute lymphoblastic leukemia. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[16] Laurence L. George,et al. The Statistical Analysis of Failure Time Data , 2003, Technometrics.
[17] S. Armstrong,et al. Gene expression signatures in MLL-rearranged T-lineage and B-precursor acute leukemias: dominance of HOX dysregulation. , 2003, Blood.
[18] Sho Hashimoto,et al. APAF-1-ALT, a novel alternative splicing form of APAF-1, potentially causes impeded ability of undergoing DNA damage-induced apoptosis in the LNCaP human prostate cancer cell line. , 2003, Biochemical and biophysical research communications.
[19] J. Downing,et al. Treatment-specific changes in gene expression discriminate in vivo drug response in human leukemia cells , 2003, Nature Genetics.
[20] M. D. Den Boer,et al. Sensitivity to L-asparaginase is not associated with expression levels of asparagine synthetase in t(12;21)+ pediatric ALL. , 2003, Blood.
[21] S. Armstrong,et al. Differential mRNA expression of Ara-C-metabolizing enzymes explains Ara-C sensitivity in MLL gene-rearranged infant acute lymphoblastic leukemia. , 2003, Blood.
[22] Mian Wu,et al. Bcl‐rambo beta, a special splicing variant with an insertion of an Alu‐like cassette, promotes etoposide‐ and Taxol‐induced cell death , 2003, FEBS letters.
[23] T. Hongo,et al. Two Groups of Philadelphia Chromosome—Positive Childhood Acute Lymphoblastic Leukemia Classified by Pretreatment Multidrug Sensitivity or Resistance in In Vitro Testing , 2002, International journal of hematology.
[24] H. Findley,et al. MDM2 induces NF-kappaB/p65 expression transcriptionally through Sp1-binding sites: a novel, p53-independent role of MDM2 in doxorubicin resistance in acute lymphoblastic leukemia. , 2002, Blood.
[25] J. Downing,et al. Classification, subtype discovery, and prediction of outcome in pediatric acute lymphoblastic leukemia by gene expression profiling. , 2002, Cancer cell.
[26] D. Campana,et al. Childhood acute lymphoblastic leukaemia--current status and future perspectives. , 2001, The Lancet. Oncology.
[27] M. Tomonaga,et al. Aberrant expression of caspase cascade regulatory genes in adult T‐cell leukaemia: survivin is an important determinant for prognosis , 2001, British journal of haematology.
[28] F. Martinon,et al. Bcl-rambo, a Novel Bcl-2 Homologue That Induces Apoptosis via Its Unique C-terminal Extension* , 2001, The Journal of Biological Chemistry.
[29] J. Raemaekers,et al. A novel method to compensate for different amplification efficiencies between patient DNA samples in quantitative real-time PCR. , 2001, The Journal of molecular diagnostics : JMD.
[30] Y. Lazebnik,et al. Evaluation of Apaf-1 and procaspases-2, -3, -7, -8, and -9 as potential prognostic markers in acute leukemia. , 2000, Blood.
[31] M. Hengartner. The biochemistry of apoptosis , 2000, Nature.
[32] L. Corcos,et al. Positive and negative regulation of apoptotic pathways by cytotoxic agents in hematological malignancies , 2000, Leukemia.
[33] R. Pieters,et al. TEL/AML1 gene fusion is related to in vitro drug sensitivity for L-asparaginase in childhood acute lymphoblastic leukemia. , 2000, Blood.
[34] J C Reed,et al. Expression and prognostic significance of IAP-family genes in human cancers and myeloid leukemias. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.
[35] Guido Kroemer,et al. Mitochondrial control of cell death , 2000, Nature Medicine.
[36] S. Pollefeyt,et al. Three differentially expressed survivin cDNA variants encode proteins with distinct antiapoptotic functions. , 2000, Blood.
[37] T. Hongo,et al. Biological characteristics and prognostic value of in vitro three-drug resistance to prednisolone, L-asparaginase, and vincristine in childhood acute lymphoblastic leukemia. , 1999, International journal of hematology.
[38] D. Nicholson,et al. Caspase structure, proteolytic substrates, and function during apoptotic cell death , 1999, Cell Death and Differentiation.
[39] GS Salomons,et al. Bcl-2 family members in childhood acute lymphoblastic leukemia: relationships with features at presentation, in vitro and in vivo drug response and long-term clinical outcome , 1999, Leukemia.
[40] H. Stein,et al. Three new types of Apaf-1 in mammalian cells. , 1999, Biochemical and biophysical research communications.
[41] Robert Gray,et al. A Proportional Hazards Model for the Subdistribution of a Competing Risk , 1999 .
[42] A. Hall,et al. Increased BAX expression is associated with an increased risk of relapse in childhood acute lymphocytic leukemia. , 1999, Blood.
[43] D. Seol,et al. A Caspase-9 Variant Missing the Catalytic Site Is an Endogenous Inhibitor of Apoptosis* , 1999, The Journal of Biological Chemistry.
[44] C. Rudin,et al. Signal transduction pathways that regulate cell survival and cell death , 1998, Oncogene.
[45] M. D. Boer,et al. Relation between age, immunophenotype and in vitro drug resistance in 395 children with acute lymphoblastic leukemia–implications for treatment of infants , 1998, Leukemia.
[46] F. Behm,et al. Early intensification of intrathecal chemotherapy virtually eliminates central nervous system relapse in children with acute lymphoblastic leukemia. , 1998, Blood.
[47] S. Srinivasula,et al. Autoactivation of procaspase-9 by Apaf-1-mediated oligomerization. , 1998, Molecular cell.
[48] C. Croce,et al. Expression of apoptosis-regulating proteins in chronic lymphocytic leukemia: correlations with In vitro and In vivo chemoresponses. , 1998, Blood.
[49] N. Heerema,et al. Biology and treatment of childhood T-lineage acute lymphoblastic leukemia. , 1998, Blood.
[50] J. Etxeberria,et al. Resistance to apoptosis correlates with a highly proliferative phenotype and loss of Fas and CPP32 (caspase‐3) expression in human leukemia cells , 1998, International journal of cancer.
[51] S. Srinivasula,et al. Cytochrome c and dATP-Dependent Formation of Apaf-1/Caspase-9 Complex Initiates an Apoptotic Protease Cascade , 1997, Cell.
[52] Matthias Mann,et al. FLICE is activated by association with the CD95 death‐inducing signaling complex (DISC) , 1997, The EMBO journal.
[53] T. Hongo,et al. In vitro drug sensitivity testing can predict induction failure and early relapse of childhood acute lymphoblastic leukemia. , 1997, Blood.
[54] D. Green,et al. The Release of Cytochrome c from Mitochondria: A Primary Site for Bcl-2 Regulation of Apoptosis , 1997, Science.
[55] H. Sather,et al. Improved clinical outcome for children with T-lineage acute lymphoblastic leukemia after contemporary chemotherapy: a Children's Cancer Group Study. , 1996, Leukemia & lymphoma.
[56] W. Wilmanns,et al. Association of bcl-2, bax, bcl-xL and interleukin-1 beta-converting enzyme expression with initial response to chemotherapy in acute myeloid leukemia. , 1996, Leukemia.
[57] R. Pieters,et al. Clinical and cell biological features related to cellular drug resistance of childhood acute lymphoblastic leukemia cells. , 1995, Leukemia & lymphoma.
[58] Arul M. Chinnaiyan,et al. FADD, a novel death domain-containing protein, interacts with the death domain of fas and initiates apoptosis , 1995, Cell.
[59] R. Pieters,et al. Favorable prognosis of hyperdiploid common acute lymphoblastic leukemia may be explained by sensitivity to antimetabolites and other drugs: results of an in vitro study. , 1995, Blood.
[60] R. Pieters,et al. Mononuclear cells contaminating acute lymphoblastic leukaemic samples tested for cellular drug resistance using the methyl-thiazol-tetrazolium assay. , 1994, British Journal of Cancer.
[61] M. D’Incalci,et al. Apoptosis Biochemical events and relevance to cancer chemotherapy , 1992, FEBS letters.
[62] R. Pieters,et al. Relation of cellular drug resistance to long-term clinical outcome in childhood acute lymphoblastic leukaemia , 1991, The Lancet.
[63] J. Kalbfleisch,et al. The Statistical Analysis of Failure Time Data , 1980 .
[64] Andy Greenfield,et al. Using DNA microarrays. , 2008, Methods in molecular biology.
[65] M. Toi,et al. Nuclear factor-kappaB inhibitors as sensitizers to anticancer drugs. , 2005, Nature reviews. Cancer.
[66] Jelle J. Goeman,et al. A global test for groups of genes: testing association with a clinical outcome , 2004, Bioinform..
[67] C. Willman. Discovery of novel molecular classification schemes and genes predictive of outcome in leukemia. , 2004, The hematology journal : the official journal of the European Haematology Association.
[68] T. Uchiyama,et al. Possible role of ceramide as an indicator of chemoresistance: decrease of the ceramide content via activation of glucosylceramide synthase and sphingomyelin synthase in chemoresistant leukemia. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.
[69] G. Núñez,et al. Expression and Functional Analysis of Apaf-1 Isoforms EXTRA WD-40 REPEAT IS REQUIRED FOR CYTOCHROME c BINDING AND REGULATED ACTIVATION OF PROCASPASE-9* , 2000 .
[70] F. Behm,et al. Hyperdiploid acute lymphoblastic leukemia with 51 to 65 chromosomes: a distinct biological entity with a marked propensity to undergo apoptosis. , 1999, Blood.
[71] R. Pieters,et al. In vitro cellular drug resistance and prognosis in newly diagnosed childhood acute lymphoblastic leukemia. , 1997, Blood.
[72] Y. Benjamini,et al. Controlling the false discovery rate: a practical and powerful approach to multiple testing , 1995 .
[73] S. Sen. Biochemical events and relevance to cancer chemotherapy , 1992 .
[74] R. Gray. A Class of $K$-Sample Tests for Comparing the Cumulative Incidence of a Competing Risk , 1988 .